Products
Ongericimab Biosimilar Monoclonal Antibody (PCSK9) for Research
Pre-Made Ongericimab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ongericimab (formerly JS 002) is a recombinant humanised anti-PCSK9 monoclonal antibody, for subcutaneous injection, being developed by Shanghai Junshi.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-403-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Ongericimab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody |
| INN Name | Ongericimab |
| Target | PCSK9 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Shanghai Junshi Biosciences |
| Conditions Approved | na |
| Conditions Active | Hypercholesterolemia |
| Conditions Discontinued | na |
| Development Tech | na |
About target - PCSK9
1. Protein Proprotein convertase subtilisin/kexin type 9
2. Gene PCSK9
3. Organism Homo sapiens (Human)
Function
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658).
Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827).
Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751).
Inhibits epithelial Na+ channel (ENaC)-mediated Na+ absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Cofactori
Ca2+
Activity regulationi
Its proteolytic activity is autoinhibited by the non-covalent binding of the propeptide to the catalytic domain. Inhibited by EGTA.
